 |
PRESS
RELEASE
Dr.
Giancarlo Mennella, M.D. Named to Advisory Board
Charlotte, North Carolina
(September 7, 2004) – BurnsAdler
Pharmaceuticals, Inc. announced today that Dr. Giancarlo Mennella,
M.D., has been added to the company's advisory board. Dr.
Mennella is currently Managing Director - International of
Bourne Partners, a healthcare focused investment banking firm
and a Director of Bannert Manlik in Germany. Prior to joining
Bourne Partners Dr. Mennella was the Director of Business
Development at Shire Pharmaceuticals. Shire is the third largest
UK pharmaceuticals group and is listed on the LSE, NASDAQ
and Toronto stock exchanges. Dr. Mennella was in charge of
Euro-Asian business development and has led or been involved
with several product and corporate partnering transactions.
He was also responsible for all business development efforts
in Japan, the world's second largest pharmaceutical market.
Prior to joining Shire, Dr. Mennella was Head of Business
Development for Sigma-Tau.
Banks
Bourne, President of BurnsAdler remarked, "I am pleased to
have Giancarlo involved in our advisory board at BurnsAdler.
His experience in cross border transactions and international
commercialization will uncover new product opportunities for
us in our focus markets of Latin America, Canada and Europe."
BurnsAdler
is a specialty pharmaceutical company that in-licenses and
promotes products in Europe, South America, Latin America,
Canada and the Caribbean. BurnsAdler's portfolio currently
includes products in the following fields: cardiovascular,
orthopaedic, anti-epileptic and hospital.
For additional information
about this news release contact Bryan Somerville at +1.704.552.8410
Ext. 223. For additional information about BurnsAdler, please
refer to the company's website at www.burnsadler.com.
|
BurnsAdler provides cost effective international product distribution and promotion for select emerging pharmaceutical companies.
 Print this page.
|
